Compugen/Diagnostic Products Corp.
This article was originally published in The Gray Sheet
Executive Summary
Immunoassay and nucleic-acid based diagnostics corresponding to Compugen biomarkers will be developed and commercialized by DPC under a collaborative agreement, announced Sept. 8. Resulting products will leverage Compugen's LEADS discovery technology and center on cancer and cardiovascular areas. Compugen will receive development milestone payments and royalties...